Transcriptome analysis of a clinical phase Ia Mycobacterium bovis BCG vaccination study (sex and age matched European (Caucasian) males, 25-35 years, performed in Germany)
Ontology highlight
ABSTRACT: Global transcriptome analyses provide an excellent basis for the identification and definition of biomarkers with high relevance in infection processes, therapeutic intervention and protective immunity. The measurement applies three different state of the art transcriptomic technologies for global expression profiling to vaccine development. Different microarray platforms in conjunct to next generation sequencing (NGS) will build the basis for comparative approaches, such as up-down classification and correlation coefficients. This measurement is based on Agilent microarrays and a clinical trial phase Ia study with M. bovis BCG vaccination, using two different tuberculin skin test (PPD negative and PPD positive) groups. � Surrogate measurement using PBMCs � 4 time points: d0 (naïve, pre-immunization) and d29, d57, d180 post m. bovis BCG immunization � Responses of PPD negative and PPD positive study groups � Group size of approximately 9 individuals European network of vaccine research and development (TRANSVAC) Microarray experiments were performed as single-color hybridizations using Agilent Technologies whole human genome 4x44K microarrays
ORGANISM(S): Homo sapiens
SUBMITTER: Hans-Joachim Mollenkopf
PROVIDER: E-GEOD-51059 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA